| Name | Title | Contact Details |
|---|
The Orb® Platform automatically syncs health data from your doctor and your apps and wearable devices so you can own it, gives you context so can understand it and helps you improve it so you can transform. For consumers and patients, the Orb® Platform is a cloud-based health management platform that syncs and stores your personal health data from multiple doctor’s offices as well as your apps and wearable devices. On your computer or mobile device, Orb provides you with instant clarity and understanding behind your data while also providing actionable insight and solutions to help improve your health. For providers, the Orb® Platform enables physicians to have more oversight and understanding of their patient populations. Orb connects with both the provider’s current lab networks and/or electronic health record systems as well as the patients` external lab networks to support providers with comprehensive insights into the patient’s lab data. The Orb® Platform also enables providers to quickly identify, contact and support at-risk patient populations. Orb Health has strategically established data connectivity to 120 laboratory networks, 30 EMR platforms, and over 150 wearable devices and apps.
Health Sphere Wellness Center is a Brentwood, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Axiom is a Yardley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.